Гарантії захисту прав громадян України, які працюють за кордоном

Журба, О. В. Гарантії захисту прав громадян України, які працюють за кордоном / О. В. Журба // Вісник Харківського національного університету внутрішніх справ. - 2008. – Вип. 42. - С. 306-310Досліджено та встановлено міжнародно-правові акти, що регулюють питання захисту прав трудящих-мігрантів. З’ясовано, які кроки зроблені Україною для захисту прав зазначеної категорії працівників. Исследованы и установлены международно-правовые акты, регулирующие вопросы защиты прав трудящихся-мигрантов. Выяснено, какие шаги предприняты Украиной для защиты прав указанной категории работников. Investigated and established international legal acts governing the protection of the rights of migrant workers. It was found out what steps Ukraine has taken to protect the rights of this category of workers

Dermadez modern prepara-tion for treatment of cows with purulent pododermatites

крс, гнойный пододерматит, лечение, дермаде

ПРИМУСОВЕ ПЕРЕСЕЛЕННЯ ПОЛЯКІВ І НІМЦІВ ІЗ ПРИКОРДОННОЇ ЗОНИ УCРР (1935–1936 РР.): ПЕРЕБІГ, СПРИЙНЯТТЯ, ОПІР

У статті аналізується депортація поляків та німців із районів, що біля західного кордону УСРР, яку організувала радянська влада протягом 1935–1936 рр. З’ясовано причини та описано перебіг переселення цих етноспільнот з прикордонних територій. Охарактеризовано організаційні заходи влади, що мали забезпечити підготовку селян до від’їзду. Проаналізовано розмови, котрі циркулювали у колі переселенців на тему з’ясування причин їхнього становища та несприятливих умов проживання на новому місці. Окреслено форми спротиву польського та німецького селянства владі у ході переселенської кампанії. Ключові слова: поляк, німець, переселенець, депортація, радянська влада, Україна

Службова дисципліна як складова навчання у вищих навчальних закладах системи МВС

Журба, О. В. Службова дисципліна як складова навчання у вищих навчальних закладах системи МВС / О. В. Журба // Вісник Харківського національного університету внутрішніх справ. - 2007. – Вип. 38. - С. 267-273Підкреслено, що особливої уваги потребує процес навчання у вищих навчальних закладах системи МВС України як важливе джерело поповнення системи МВС кадровим потенціалом «вищого ґатунку», фахівцями-правоохоронцями. Зауважено, що навчання у вищих закладах системи МВС докорінно відрізняється від навчання цивільного спрямування. Надані рекомендації щодо поліпшення стану дисципліни. Подчеркнуто, что особого внимания требует процесс обучения в высших учебных заведениях системы МВД Украины как важный источник пополнения системы МВД кадровым потенциалом «высшего сорта», специалистами-правоохранителями. Отмечено, что обучение в высших учебных заведениях системы МВД в корне отличается от обучения гражданского направления. Даны рекомендации по улучшению состояния дисциплины. It was emphasized that the process of training at higher educational institutions of the Ministry of Internal Affairs of Ukraine requires special attention as an important source of replenishing the Ministry of Internal Affairs system with “top-grade” personnel potential and law enforcement specialists. It is noted that education at higher educational institutions of the Ministry of Internal Affairs system is fundamentally different from civilian education. Recommendations on improving the discipline are given

Spatial datasets of radionuclide contamination in the Ukrainian Chernobyl Exclusion Zone

The dataset “Spatial datasets of radionuclide contamination in the Ukrainian Chernobyl Exclusion Zone” was developed to enable data collected between May 1986 (immediately after Chernobyl) and 2014 by the Ukrainian Institute of Agricultural Radiology (UIAR) after the Chernobyl accident to be made publicly available. The dataset includes results from comprehensive soil sampling across the Chernobyl Exclusion Zone (CEZ). Analyses include radiocaesium (134Cs and 134Cs) 90Sr, 154Eu and soil property data; plutonium isotope activity concentrations in soil (including distribution in the soil profile); analyses of “hot” (or fuel) particles from the CEZ (data from Poland and across Europe are also included); and results of monitoring in the Ivankov district, a region adjacent to the exclusion zone. The purpose of this paper is to describe the available data and methodology used to obtain them. The data will be valuable to those conducting studies within the CEZ in a number of ways, for instance (i) for helping to perform robust exposure estimates to wildlife, (ii) for predicting comparative activity concentrations of different key radionuclides, (iii) for providing a baseline against which future surveys in the CEZ can be compared, (iv) as a source of information on the behaviour of fuel particles (FPs), (v) for performing retrospective dose assessments and (vi) for assessing natural background dose rates in the CEZ. The CEZ has been proposed as a “radioecological observatory” (i.e. a radioactively contaminated site that will provide a focus for long-term, radioecological collaborative international research). Key to the future success of this concept is open access to data for the CEZ. The data presented here are a first step in this process. The data and supporting documentation are freely available from the Environmental Information Data Centre (EIDC) under the terms and conditions of the Open Government Licence: https://doi.org/10.5285/782ec845-2135-4698-8881-b38823e533bf

Алгоритм построения оптимальных пар фильтров кодирования и восстановления, адаптивных к функции многих переменных

Розглянуто алгоритм побудови оптимальних пар фільтрів будь-якої складності кодування і відновлення, адаптивних до функції багатьох змінних, для довільного регулярного паркету.An algorithm for development of optimal pairs of filters of any complexity for (coding and recovery which are) adaptive to multivariable function is proposed.Рассмотрен алгоритм построения оптимальных пар фильтров произвольной сложности кодирования и восстановления, адаптивных к функции многих переменных, для любого регулярного паркета

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)